Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) announced it will host a business update webcast on Thursday, March 26, at 11:30 a.m. Eastern time, featuring Dr. Babar K. Rao, …
Medicus Pharma to Host Business Update Call Featuring Clinical Investigator Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) reported additional data from its Phase 2 SKNJCT-003 clinical study evaluating the SkinJect microneedle delivery system for the treatment of basal cell …
Medicus Reports Phase 2 Results for SkinJect Basal Cell Carcinoma Study Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported topline results from a Phase 2 clinical trial evaluating its Doxorubicin Microneedle Array treatment for basal cell carcinoma of the skin.
Medicus Pharma Reports Phase 2 Results for Basal Cell Carcinoma Therapy Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) announced it will participate in the 38th Annual Roth Conference, scheduled for March 22 to March 24 in Dana Point, California.
Medicus Pharma to Present Drug Development Programs at Roth Conference Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported topline results from a Phase 2 clinical trial evaluating a dissolvable microneedle patch designed to deliver chemotherapy directly into basal cell …
Medicus Pharma Reports Phase 2 Results for Skin Cancer Patch Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said it has received “study may proceed” clearance from the U.S. Food and Drug Administration to initiate a Phase 2b dose-optimization trial …
Medicus Pharma Receives FDA Clearance to Begin Phase 2b Teverelix Study Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) has received clearance from the U.S. Food and Drug Administration to proceed with a Phase 2b clinical study of Teverelix, a long-acting …
FDA Clears Medicus to Advance Prostate Cancer Drug Aimed at Heart-Risk Patients Read More PHILADELPHIA, PA — Medicus Pharma (NASDAQ: MDCX) has reworked the economics of its lead urology and oncology program, cutting royalty obligations tied to Teverelix in half while preserving full global …
Medicus Slashes Teverelix Royalty, Sharpens Path to $6B Market Opportunity Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) marked its first anniversary as a publicly traded company on Thursday by ringing the Nasdaq Opening Bell at the Nasdaq MarketSite in …
Bell Rings on Wall Street as Medicus Marks One Year as Nasdaq Player Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said detailed clinical data from early-stage studies of its long-acting hormone-suppressing drug Teverelix have been accepted for presentation at a major international …
Medicus Gene-Blocking Drug Shows Fast Hormone Control Ahead of Key Endocrine Meet Read More